← Eichor
Study identifier: NCT06832046 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Evaluation of the "Intranasal Fentanyl" Protocol in Pediatric Surgical Emergencies at Strasbourg University Hospital

Condition: Musculoskeletal Pain  ·  Sponsor: University Hospital, Strasbourg, France

PhaseN/A
Planned participants500
Who can joinAll sexes, 1 Year to 17 Years
Healthy volunteersNo

About this study

Emergency trauma departments receive thousands of patients each year whose main symptom is pain. In recent years, intranasal fentanyl (FIN) has entered the therapeutic arsenal to treat pain in the emergency department. Various studies have validated its effectiveness for musculoskeletal pain as well as its tolerance and safety of use. Since then, new protocols have been implemented including this treatment. In This study, the investigators propose to retrospectively study the quality of prescription of intranasal fentanyl in the treatment of pain in the emergency department and the quality of monitoring of this treatment in current practice.

This description comes directly from the study's public registry record.

Talk to the study team

Dimitar TCHOMAKOV, MD  ·  33 3 88 12 81 18  ·  Dimitar.tchomakov@chru-strasbourg.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Service d'Urgences Médico-Chirurgicales Pédiatriques - CHU de Strasbourg - FranceStrasbourg, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06832046